New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma

Dateline City:

KENILWORTH, N.J.

KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients
Results from KEYNOTE-028 Presented at 2015 European Cancer Congress

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings investigating
the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy, as a monotherapy in patients with advanced unresectable
nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose
tumors express PD-L1 (≥1% of cells in tumor nests or PD-L1+ bands in
stroma).
Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]An Phan, (908) 255-6325orInvestor:Justin Holko, [phone]Teri Loxam, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Corporate News - September 26, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news